Shares of Regencell Bioscience Limited (RGC) experienced a sharp decline, plummeting 18.69% during Thursday's night session. This significant drop follows a similar 18% tumble on Wednesday, marking a continued downward trend for the biotech company.
The steep sell-off appears to be driven by investors reassessing the company's valuation in light of a recent stock split announcement. This reassessment comes on the heels of an extraordinary rally that saw Regencell's stock surge by an astonishing 59,900% year-to-date, a move that raised eyebrows given the company's lack of reported revenue.
Market analysts suggest that the current correction could be a natural pullback after such a meteoric rise, especially considering the absence of fundamental financial performance to support the previous valuation. As investors digest the implications of the stock split and reevaluate the company's prospects, the stock may continue to face volatility in the near term.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。